Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus
Nicolas Salvadori, Bo Fan, Waralee Teeyasoontranon, Nicole Ngo-Giang-Huong, Siriluk Phanomcheong, Anita Luvira, Achara Puangsombat, Arunrat Suwannarat, Ussanee Srirompotong, Chaiwat Putiyanun, Tim R Cressey, Luc Decker, Woottichai Khamduang, Linda Harrison, Camlin Tierney, John A Shepherd, Athena P Kourtis, Marc Bulterys, George K Siberry, Gonzague Jourdain, Nicolas Salvadori, Bo Fan, Waralee Teeyasoontranon, Nicole Ngo-Giang-Huong, Siriluk Phanomcheong, Anita Luvira, Achara Puangsombat, Arunrat Suwannarat, Ussanee Srirompotong, Chaiwat Putiyanun, Tim R Cressey, Luc Decker, Woottichai Khamduang, Linda Harrison, Camlin Tierney, John A Shepherd, Athena P Kourtis, Marc Bulterys, George K Siberry, Gonzague Jourdain
Abstract
In a randomized, double-blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks gestational age to 2 months postpartum to prevent mother-to-child transmission of hepatitis B virus, there was no significant effect of maternal TDF use on maternal or infant bone mineral density 1 year after delivery/birth. Clinical Trials Registration. NCT01745822.
Keywords: bone mineral density; growth; hepatitis B; pregnancy; tenofovir disoproxil fumarate.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Source: PubMed